Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239926 · ClinicalTrials.gov registry record · Phase 2
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02239926: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02239926 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239926, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?
Primary Outcome
BSS is a 100-mm visual analog scale for each symptom of Irritable Bowel Syndrome (IBS) (pain or discomfort, bloating, and diarrhea) with an overall severity score. Lower scores indicate symptoms are not present and higher scores indicate severe symptoms.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Why NCT02239926 stopped before completion
NCT02239926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02239926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02239926 about?
NCT02239926 is a clinical study titled "Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D". Will Ranolazine improve bowel function and abdominal pain in human subjects with IBS-D?
What is the current status of trial NCT02239926?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02239926?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT02239926?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02239926's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia